check_circleStudy Completed
Ophthalmology, Macular Degeneration
Bayer Identifier:
20285
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
A follow-up physician survey to evaluate physician knowledge of safety and safe use information for Aflibercept administered by intravitreal injection in Europe
Trial purpose
With this follow up physician survey researcher want to collect the same data from all participants of the study using a highly structured questionnaire. The questionnaire will gather information related to physician characteristics and experience with Aflibercept, as well as assess physicians’ knowledge and understanding of storage and preparation, proper injection technique, and the risks associated with Aflibercept injection into the eye (intravitreal injection). Analysis will be done using descriptive statistics.
Key Participants Requirements
Sex
AllAge
NaN - N/ATrial summary
Enrollment Goal
454Trial Dates
October 2019 - April 2020Phase
N/ACould I Receive a placebo
NoProducts
Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)Accepts Healthy Volunteer
YesWhere to participate
Status | Institution | Location |
---|---|---|
Completed | Many locations | Many locations, Germany |
Primary Outcome
- Percentage of physicians responding correctly to each individual knowledge questiondate_rangeTime Frame:Up to 1 year
Trial design
Trial Type
ObservationalIntervention Type
OtherTrial Purpose
N/AAllocation
N/ABlinding
N/AAssignment
N/ATrial Arms
N/A